Marzieh Rohani-Rasaf

Dr. Marzieh Rohani-Rasaf

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

19 April 2021 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
FZFariba Zare
Fariba Zare
MTMaryam Teimouri
Maryam Teimouri
AKAhmad Khosravi
Ahmad Khosravi
MRMarzieh Rohani-Rasaf
Marzieh Rohani-Rasaf
RCReza Chaman
Reza Chaman
Mohammad Hassan EmamianMohammad Hassan Emamian
Mohammad Hassan Emamian
Although many people became infected and recovered during the COVID-19 epidemic, the immunity duration and re-infection in recovered patients have recently attracted many researchers. The aim of this study was to evaluate the recurrence of the infection in recovered individuals over a 9-month period after the onset of the COVID-19 epidemic. In this study, data related to COVID-19 patients in Shahroud city were collected using the electronic system for registering suspicious patients and also by checking patients' hospital records. In this study, from 20 March 2020 to 20 November 2020 (9 months), a total of 8734 suspected patients with respiratory symptoms were observed and followed up. RT-PCR was positive for 4039 patients. During this period, out of the total number of positive cases of COVID-19, 10 cases became re-infected after complete recovery. The risk of re-infection was 2.5 per thousand (0.95 CI 1.2-4.5). The mean time interval between the first infection and re-infection was 134.4 +/- 64.5 days (range 41-234 days). The risk of re-infection between male and females was not statistically different (1.98 per 1000 women and 2.96 per 1000 men). Exposure to COVID-19 may not establish long-term protective immunity to all patients and may predispose them to re-infection. This fact can be reminded that the use of masks, social distancing and other preventive measures are very important in recovered patients and should be emphasised especially in health care personnel who are more exposed to the virus.

10 June 2020 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
AKA. Khosravi
A. Khosravi
RCR. Chaman
R. Chaman
MRMarzieh Rohani-Rasaf
Marzieh Rohani-Rasaf
FZF. Zare
F. Zare
Shiva MehravaranShiva Mehravaran
Shiva Mehravaran
Mohammad Hassan EmamianMohammad Hassan Emamian
Mohammad Hassan Emamian
The aim of this study was to estimate the basic reproduction number (R 0) of COVID-19 in the early stage of the epidemic and predict the expected number of new cases in Shahroud in Northeastern Iran. The R 0 of COVID-19 was estimated using the serial interval distribution and the number of incidence cases. The 30-day probable incidence and cumulative incidence were predicted using the assumption that daily incidence follows a Poisson distribution determined by daily infectiousness. Data analysis was done using ‘earlyR’ and ‘projections’ packages in R software. The maximum-likelihood value of R 0 was 2.7 (95% confidence interval (CI): 2.1−3.4) for the COVID-19 epidemic in the early 14 days and decreased to 1.13 (95% CI 1.03–1.25) by the end of day 42. The expected average number of new cases in Shahroud was 9.0 ± 3.8 cases/day, which means an estimated total of 271 (95% CI: 178–383) new cases for the period between 02 April to 03 May 2020. By day 67 (27 April), the effective reproduction number (R t), which had a descending trend and was around 1, reduced to 0.70. Based on the R t for the last 21 days (days 46–67 of the epidemic), the prediction for 27 April to 26 May is a mean daily cases of 2.9 ± 2.0 with 87 (48–136) new cases. In order to maintain R below 1, we strongly recommend enforcing and continuing the current preventive measures, restricting travel and providing screening tests for a larger proportion of the population.

8 August 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
AAAnita Aminzadeh
Anita Aminzadeh
NANazanin Azmi-Naei
Nazanin Azmi-Naei
MTMaryam Teimouri
Maryam Teimouri
MRMarzieh Rohani-Rasaf
Marzieh Rohani-Rasaf
Background: Simple and cost-effective biochemical markers are still very useful for predicting severity and mortality in COVID-19 patients. This study investigates the association of some inflammatory and also non-invasive biochemical indices of liver function and critical care outcomes of COVID-19 patients. Methods: In this cross-sectional study, a total of 2232 hospitalized COVID-19 patients, regardless of the presence of underlying liver diseases, were followed. Based on the laboratory results at the time of admission, five indices—FIB-4 (Fibrosis-4), NLR (Neutrophil to Lymphocyte Ratio), APRI (Aspartate Aminotransferase to Platelet Ratio), ALRI (Aspartate Aminotransferase to Lymphocyte Ratio), and SII (Systemic Immune-Inflammation)—were calculated. Results: According to the results of multivariate regression, all five indices were predictors of mortality and severity in COVID-19 patients after adjusting for age, sex, comorbidities and BMI. The odds ratios for FIB-4, NLR, APRI, ALRI, and SII to predict mortality were 1.14 (1.07–1.21), 1.07 (1.04–1.1), 1.28 (1.12–1.46), 2.44 (1.76–3.38), and 1.57 (1.13–2.17), respectively. For predicting severity, the odds ratios were 1.22 (1.15–1.30), 1.09 (1.06–1.11), 1.78 (1.44–2.21), 1.73 (1.41–2.14), and 1.27 (1.04–1.57), respectively. Additionally, based on the AUC results, FIB-4 and NLR indices demonstrated the best performance in predicting COVID-19 mortality and severity, respectively. Conclusions: Our results show that the non-invasive biochemical indices of liver function, NLR, and SII can be useful as early predictors of severity and mortality in COVID-19 patients.

1 January 2020 in IDCases
Verified
Journal Article
Open access
SMSepideh Mahdavi
Sepideh Mahdavi
Amirhessam KheiriehAmirhessam Kheirieh
Amirhessam Kheirieh
SDSalman Daliri
Salman Daliri
MKMohammad Hossein Kalantar
Mohammad Hossein Kalantar
MVMaryam Valikhani
Maryam Valikhani
MRMarzieh Rohani-Rasaf
Marzieh Rohani-Rasaf
The present study investigated an 18-days-old neonate who was referred to the hospital with suspected respiratory symptoms of COVID-19. Results of CT-Scan and blood tests were highly suspicious, but result of the first RT-PCR test was negative on March 1. The second RT-PCR test reported positive on March 12. The neonate's medical history indicated no close contact except with family members and hospital treatment staffs, but the RT-PCR test results of all family members were also negative.

7 May 2022 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
EKErfan Kazemi
Erfan Kazemi
AMAli Mansoursamaei
Ali Mansoursamaei
MRMarzieh Rohani-Rasaf
Marzieh Rohani-Rasaf
HSHossein Sheibani
Hossein Sheibani
Background: Serum vitamin D levels may have a protective role against severe coronavirus disease 2019 (COVID-19). Studies have shown that deficiency in vitamin D may be a significant risk factor for poor outcomes. This study aims to compare the outcome and clinical condition of patients diagnosed with COVID-19 infection considering serum vitamin D levels.Methods: In this cross-sectional study, 202 COVID-19 patients without known cardiovascular disease (reduced ejection fraction, uncontrolled arrhythmia, pericardial effusion, cardiac block, valvular disease, or hypertension) were included. Patients were divided into three groups of insufficient (< 30 ng/mL), normal (30 to 50 ng/mL), and high (> 50 ng/mL) serum vitamin D levels. Clinical outcome was defined as severe if invasive respiratory intervention and ICU admission was required.Results: The patients were divided into three groups based on their vitamin D level: 127 cases in the insufficient vitamin D group, 53 cases in the normal vitamin D group, and 22 cases in the high vitamin D group. The mean age of the population study was 56 years. Thirty-four patients had severe clinical outcomes. The distribution of this group was as follows: 21 patients in the insufficient vitamin D group (16.5%), eight patients in the normal vitamin D group (15.1%), and five patients in the high vitamin D group (22.7%); P = 0.74. No significant differences were found between the groups in terms of mortality rate (P = 0.46). Moreover, the mean of leukocytes (mean ± SD = 6873.5 ± 4236.2), ESR (mean ± SD = 38.42 ± 26.7), and CPK-MB (mean ± SD = 63 ± 140.7) were higher in the insufficient vitamin D group, but it was not statistically significant (P > 0.05).Conclusion: The finding of the present study showed that vitamin D could not make a significant difference in cardiovascular systems, laboratory results, and severity of the disease in COVID-19 patients.